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Abstract 
 
Background 
A clinical trial of cyclosporine in patients with steroid-resistant focal segmental 
glomerulosclerosis (FSGS) was conducted. Despite the fact that it is the most 
common primary glomerulonephritis to progress to renal failure, treatment 
trials have been very limited. 
 
Methods 
We conducted a randomized controlled trial in 49 cases of steroid-resistant 
FSGS comparing 26 weeks of cyclosporine treatment plus low-dose 
prednisone to placebo plus prednisone. All patients were followed for an 
average of 200 weeks, and the short- and long-term effects on renal function 
were assessed. 
 
Results 
Seventy percent of the treatment group versus 4% of the placebo group (P < 
0.001) had a partial or complete remission of their proteinuria by 26 weeks. 
Relapse occurred in 40% of the remitters by 52 weeks and 60% by week 78, 
but the remainder stayed in remission to the end of the observation period. 
Renal function was better preserved in the cyclosporine group. There was a 
decrease of 50% in baseline creatinine clearance in 25% of the treated group 
compared with 52% of controls (P < 0.05). This was a reduction in risk of 70% 
(95% CI, 9 to 93) independent of other baseline demographic and laboratory 
variables. 
 
Conclusions 
These results suggest that cyclosporine is an effective therapeutic agent in 
the treatment of steroid-resistant cases of FSGS. Although a high relapse rate 
does occur, a long-term decrease in proteinuria and preservation of filtration 
function were observed in a significant proportion of treated patients. 
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